Apricus Biosciences, Inc.
Apricus Biosciences to Present at the Cowen and Company 36th Annual Health Care Conference
SAN DIEGO, 2016-03-01 13:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016, at 4:00 p.m. Eastern Time. The conference will be held at The Boston Marriott Copley Place, Boston, MA. Mr. Pascoe will provide an update on Vitaros®*, the Company's topical treatment for erectile dysfunction, as well as Apricus' drug candidates fispemifene, for the treatment of men with secondary hypogonadism and RayVa™, for the treatment of patients with Raynaud's phenomenon.
A live audio webcast of the presentation can be accessed via the Investor Relations section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 30 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus recently completed enrollment in its Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus has completed a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon, and plans to conduct additional clinical trials in patients with Raynaud’s phenomenon secondary to scleroderma. Apricus’ lead commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals) and Mylan NV. Apricus’ second-generation room temperature Vitaros is currently under development.
For further information on Apricus, visit http://www.apricusbio.com.
*Vitaros®is a registered trademark of NexMed International Limited. Such trademark is registered in certain countries throughout the world and pending registration in the United States.
Institutional / Retail Investors: Matthew Beck
The Trout Group LLC
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Vricon23.2.2018 19:22 | pressemeddelelse
Vricon launches Telco Suite at Mobile World Congress
Excel Dryer Inc.22.2.2018 16:01 | pressemeddelelse
Leading the industry: Excel Dryer is the first hand dryer manufacturer to publish third-party, verified Environmental Product Declarations (EPDs)
Magna International Inc.22.2.2018 11:02 | pressemeddelelse
Magna Announces Fourth Quarter and 2017 Results and Raises Quarterly Cash Dividend by 20%
Percona22.2.2018 09:02 | pressemeddelelse
Percona Unveils Full Conference Session Schedule for the Annual Percona Live Open Source Database Conference 2018
Taconic Biosciences21.2.2018 19:15 | pressemeddelelse
Taconic Biosciences Announces the Formation of Scientific Advisory Board
TrueCommerce21.2.2018 16:01 | pressemeddelelse
TrueCommerce Dynamics 365 Solution Featured on Microsoft AppSource
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum